YOLFTbeta
Genoray Co. Ltd

Genoray Co. Ltd

122310 · KQ · Healthcare / Diagnostics & Research

3,125.00KRW-15.00 (-0.48%)

Price History

Full chart

Market Stats

Previous Close3,140.00
Open3,100.00
Day Range3,095.00 – 3,190.00
52-Week Range3,071.25 – 5,269.48
Volume12.22K
Market Cap42.27B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield7.55%
Beta0.25
50-Day Avg3,377.30
200-Day Avg3,955.65

About

Genoray Co., Ltd. engages in the research, development, manufacture, and sale of medical and dental x-ray devices in South Korea. It provides C-ARM and mammography medical x-ray devices; and 2D, 3D, ENT, and IOS/IOX dental x-ray devices, as well as related maintenance and repair services. The company also exports its products to approximately 80 countries worldwide. Genoray Co., Ltd. was founded in 2001 and is headquartered in Seongnam-si, South Korea

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOByung Uk Park
  • Employees360
  • Headquarters3-15, Dunchon-daero 80beon-gil, Seongnam-si, South Korea, 462-716, Korea
  • Websitehttps://www.genoray.com

Leadership

  • Byung Uk ParkChief Executive Officer · b. 1962
  • Mr. JoongHyun ParkHead of Financial Management Office & CFO · b. 1975
  • Mr. Changsoo YoonHead of Future Business Team & Global Planning Office · b. 1964
  • Mr. Taehwan ChoHead of Purchasing Department · b. 1965
  • Mr. Hyupjoo ShinDirector & Head of Domestic Business Division · b. 1962
  • Mr. InSun ShinHead of Global Planning Department · b. 1971
  • Mr. InHo ChoiDirector & FLEXLAB Department Head · b. 1968
  • JaeMin AhnHead of Global Business Headquarters & Director · b. 1973

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue31.88B38.28B44.49B56.29B65.11B61.69B74.29B82.60B97.90B106.98B108.04B
Growth (%)-+20.07%+16.23%+26.52%+15.66%-5.25%+20.43%+11.19%+18.51%+9.28%+0.99%
Cost of Revenue21.03B23.69B27.94B33.31B35.91B35.71B43.30B47.34B60.35B67.45B66.39B
Gross Profit10.85B14.59B16.55B22.97B29.20B25.98B30.99B35.26B37.54B39.54B41.65B
Gross Margin34.05%38.12%37.20%40.82%44.84%42.11%41.72%42.69%38.35%36.96%38.55%
Operating Expense8.26B10.00B10.35B12.02B14.53B14.86B16.02B20.34B24.79B47.05B41.90B
Operating Income2.60B4.59B6.20B10.96B14.67B11.12B14.97B14.92B12.76B-7.51B-243.29M
Operating Margin8.15%12.00%13.94%19.47%22.53%18.03%20.15%18.06%13.03%-7.02%-0.23%
EBITDA-------19.53B17.80B2.23B8.48B
EBITDA Margin-------23.65%18.18%2.08%7.85%
Net Income2.00B3.22B5.17B9.47B13.24B10.17B14.32B13.90B12.49B-1.80B757.69M
Net Income Margin6.26%8.42%11.62%16.83%20.34%16.49%19.28%16.83%12.75%-1.68%0.70%
R&D-1.82B1.37B1.60B1.98B2.65B2.96B3.51B4.26B8.88B12.09B
R&D as % of Total Revenue-4.77%3.07%2.84%3.05%4.29%3.98%4.25%4.35%8.30%11.19%
Interest Expense00000239.21M176.22M195.09M557.87M962.52M1.12B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.39%0.24%0.24%0.57%0.90%1.04%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets28.54B33.39B37.73B58.44B78.52B85.74B99.37B106.20B124.27B123.44B131.23B
Total Liabilities17.18B18.59B13.44B13.47B18.93B19.22B20.56B18.23B28.74B37.55B47.48B
Total Equity11.35B14.80B24.30B44.97B59.59B66.53B78.82B87.96B95.35B85.89B84.49B
Cash2.62B3.26B4.13B10.21B14.52B18.47B1.98M248.00K5.17B6.93M13.84B
Total Debt-6.54B6.64B5.03B8.35B10.86B-----
Net Debt-------4.14B7.14B3.12B9.16B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow2.10B3.47B4.47B6.89B10.65B8.51B15.38B14.84B3.55B13.27B5.26B
Investing Cash Flow-2.14B-1.55B-2.44B-9.98B-8.29B-2.76B-12.29B-21.62B560.35M1.42B-
Financing Cash Flow-1.43B-1.19B-1.13B9.13B1.95B-1.78B-1.59B-8.16B-3.71B-3.85B-
Capital Expenditure2.40B1.58B830.19M1.38B1.00B566.06M5.33B9.25B8.60B6.29B1.40B
Free Cash Flow-----4.23B6.47B1.06B-1.71B6.98B3.85B
Dividends Paid-1.37B1.37B1.37B1.37B1.93B1.72B2.43B2.24B2.19B2.24B
FCF to OCF-----49.69%42.09%7.13%-48.25%52.60%73.29%
Dividend Paid to FCF-----45.57%26.49%229.47%-130.40%31.30%58.21%

Earnings

Report DateAug 14, 2018Nov 13, 2018Feb 12, 2019May 9, 2019Aug 8, 2019Oct 30, 2019Feb 4, 2020May 6, 2020Aug 4, 2020Nov 4, 2020Feb 2, 2021May 13, 2021Aug 12, 2021Nov 11, 2021Feb 25, 2022May 10, 2022Aug 3, 2022Nov 7, 2022Feb 6, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------------
EPS Actual195.4598.50258.33131.00684.24215.90337.93191.00202.00183.00132.95181.42224.78234.40361.46213.00293.00182.32300.00148.95256.37222.68284.45162.2985.1632.01-412.8910.49-143.00-82.00275.00-31.9847.62
Surprise---------------------------------
TimingPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours--------------

Key Statistics & Ratios

Market Cap42.27B
Enterprise Value58.82B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.39
Price / Book0.52
Revenue (TTM)107.88B
Gross Profit (TTM)42.48B
EBITDA7.00B
Profit Margin2.42%
Operating Margin0.94%
Return on Equity3.18%
Return on Assets-0.76%
Shares Outstanding12.73M
Shares Float8.72M
Beta0.25
Dividend Yield7.55%
Dividend Rate250.00
Payout Ratio119.82%

Dividends

20263×
50.00Jun 29, 202650.00Mar 30, 2026150.00Feb 26, 2026
20251×
180.00Apr 2, 2025
20241×
160.00Apr 2, 2024
20221×
160.00Dec 28, 2022
20211×
170.00Dec 29, 2021
20201×
120.00Dec 29, 2020
20191×
133.33Dec 27, 2019
20181×
100.00Dec 27, 2018

Stock Splits

  • Feb 21, 2020959692:319897